Study

Curated
Gabrawy et al., 2022
Genome-Wide Analysis in Drosophila Reveals the Genetic Basis of Variation in Age-Specific Physical Performance and Response to ACE Inhibition
[10.3390/genes13010143]

Description

Climbing speed and endurance (distance climbed in 15 s) were measured on virgin males of 126 DGRP lines at 1 and 5 weeks of age, on control food or on food with the ACE inhibitor Lisinopril. The effect of Lisinopril varied with genotype and age.

Comments from curator

Phenotyping data comes from the Supplementary Materials of the paper (MDPI supplementary files, genes-13-00143-s001.zip; also on PMC):
- Table S3 ("Physical performance results and means of 126 DGRP lines submitted to DGRP pipeline"): mean and standard error of the climbing speed and of the endurance of each line, at 1 and 5 weeks of age, on control and on Lisinopril food.
- Table S2 ("Sensitivity of 126 DRGP lines to Lisinopril treatment results"): the sensitivity of each trait to Lisinopril, at 1 and 5 weeks.
Only these per-line values were published. The Data Availability Statement promises that the data will be deposited in a public repository, but none was found (Dryad, Zenodo, figshare; November 2026), so the study has a summary dataset only.

Design: virgin males of 126 DGRP lines (the lines that gave enough flies at old age) were kept from eclosion on standard food (control) or on food containing 1 mM Lisinopril, an inhibitor of the angiotensin-converting enzyme (ACE; fly ortholog Ance), at 25 °C, about 55% relative humidity and 12:12 h light:dark. They were tested at 1 week (young) and 5 weeks (old) of age, between 8:00 and 14:00. Each fly was aspirated into the bottom of a 25-mL serological pipette marked at 9 and 27 cm, and tested only once, for one trait:
- Climbing speed (cm/s): speed over the first 9 cm, from the time the fly took to reach the 9-cm mark.
- Endurance (cm): the distance travelled in 15 s between the 9-cm and the 27-cm marks.
About 30 flies were measured per line, age and food, and each fly was weighed after the assay (body mass was a covariate in the authors' ANCOVA).

The summary dataset (sex M, 126 lines) has:
- mn_ClimbSpd_w1_Ctrl, mn_ClimbSpd_w1_Lis, mn_ClimbSpd_w5_Ctrl, mn_ClimbSpd_w5_Lis and the matching se_ClimbSpd_...: mean and standard error of the climbing speed at week 1 or 5 (w1, w5), on control (Ctrl) or Lisinopril (Lis) food, from Table S3.
- mn_Endurance_... and se_Endurance_...: the same for endurance, from Table S3.
- LisSensSpeed_w1, LisSensSpeed_w5, LisSensEndur_w1 and LisSensEndur_w5: Falconer's sensitivity index of climbing speed or endurance to Lisinopril, at week 1 or 5, from Table S2. It is the line mean on Lisinopril food minus the line mean on control food, divided by the average of this difference over the 126 lines, so it averages 1. Positive values mean that Lisinopril improved the trait, negative values that it worsened it. The index is 0 when both line means are equal: for endurance, 6 lines at week 5 (5 of them climbed 0 cm on both foods) and DGRP_223 at week 1. The authors computed it from the Table S3 means (checked), so it can be rederived from the mn_ phenotypes. Its ranges are as in the paper: -3.96 to 9.07 (climbing speed, week 1), -5.78 to 11.42 (week 5), -5.92 to 8.68 (endurance, week 1) and -6.32 to 11.99 (week 5). In the GWAS of the sensitivity, the authors used the trait value of the line on control or Lisinopril food as a cofactor.

Line names: the first column of Table S3 (headed "DGRP Line") holds the authors' internal numbering of their DGRP stocks (1 to 201), not DGRP line numbers. Its rows are in the same order as those of Table S2, which gives the "Genotype Identifier" (1 to 126, the numbering used in Figures 1, 2, S2 and S4) and the DGRP line. The sensitivity index recomputed from the Table S3 means of row k equals the Table S2 index of row k for all four trait and age combinations (largest difference 2 × 10-5, from rounding), and the internal number increases with the DGRP number (it is the rank of the line among the 205 DGRP lines, minus 0 to 2). Each Table S3 row was therefore assigned to the DGRP line of the same row of Table S2.

Of note:
- The methods say that the authors submitted least-squares line means adjusted for body mass (ANCOVA) to the DGRP2 web tool for the GWAS (Freeze 2, nominal P < 10-5), and Table S3 is titled "means ... submitted to DGRP pipeline". However, the Table S3 values look like plain line means: 15 of them are exactly 0 cm with a standard error of 0 (endurance at week 5, lines in which no fly climbed), which a model-adjusted mean would not give. The body-mass-adjusted means were not published. The averages of the Table S3 means over the 126 lines reproduce the overall means given in the Results: climbing speed 1.54 and 0.77 cm/s at weeks 1 and 5, and 1.11 and 1.20 cm/s on control and Lisinopril food (paper: 1.10 and 1.20); endurance 16.58 and 7.35 cm at weeks 1 and 5, and 11.38 and 12.54 cm on control and Lisinopril food (paper: 16.57, 7.34, 11.39 and 12.53; the paper averages flies, not lines).
- Endurance is defined as the distance travelled between the 9-cm and 27-cm marks (at most 18 cm), but at week 1 the line mean exceeds 18 cm for 49 lines on control food and 66 lines on Lisinopril food, and exceeds 27 cm for 2 and 3 lines (up to 29.3 cm). The paper does not say how flies that reached the 27-cm mark within 15 s were scored. The values are uploaded as published.

Not uploaded: the muscle-specific RNAi knockdowns of Axn, fz, nmo and wg (Table S7: climbing speed and endurance of dj667-GAL4 × TRiP UAS-RNAi flies and of the attP2 control; not DGRP lines), their qRT-PCR (Table S1) and the GWAS and network results (Tables S4-S6). An earlier study by the same group, on three DGRP lines (life span, climbing speed, endurance and strength on Lisinopril), is DGRPool study 87 (Gabrawy et al. 2019); its data are different.

Datasets

Dataset Phenotypes DGRP lines
Summary dataset 20 phenotypes
LisSensEndur_w1 LisSensEndur_w5 LisSensSpeed_w1 LisSensSpeed_w5 mn_ClimbSpd_w1_Ctrl mn_ClimbSpd_w1_Lis mn_ClimbSpd_w5_Ctrl mn_ClimbSpd_w5_Lis mn_Endurance_w1_Ctrl mn_Endurance_w1_Lis mn_Endurance_w5_Ctrl mn_Endurance_w5_Lis se_ClimbSpd_w1_Ctrl se_ClimbSpd_w1_Lis se_ClimbSpd_w5_Ctrl se_ClimbSpd_w5_Lis se_Endurance_w1_Ctrl se_Endurance_w1_Lis se_Endurance_w5_Ctrl se_Endurance_w5_Lis
126 DGRP lines
DGRP_021
DGRP_026
DGRP_028
DGRP_031
DGRP_032
DGRP_038
DGRP_040
DGRP_041
DGRP_045
DGRP_049
DGRP_073
DGRP_075
DGRP_083
DGRP_088
DGRP_091
DGRP_100
DGRP_101
DGRP_105
DGRP_136
DGRP_142
DGRP_149
DGRP_158
DGRP_181
DGRP_189
DGRP_195
DGRP_208
DGRP_217
DGRP_223
DGRP_227
DGRP_228
DGRP_229
DGRP_237
DGRP_239
DGRP_280
DGRP_287
DGRP_303
DGRP_304
DGRP_310
DGRP_313
DGRP_317
DGRP_319
DGRP_320
DGRP_321
DGRP_335
DGRP_336
DGRP_338
DGRP_348
DGRP_350
DGRP_352
DGRP_354
DGRP_359
DGRP_360
DGRP_362
DGRP_370
DGRP_371
DGRP_373
DGRP_374
DGRP_379
DGRP_380
DGRP_383
DGRP_385
DGRP_391
DGRP_395
DGRP_399
DGRP_406
DGRP_409
DGRP_426
DGRP_427
DGRP_439
DGRP_440
DGRP_441
DGRP_443
DGRP_486
DGRP_491
DGRP_492
DGRP_505
DGRP_508
DGRP_509
DGRP_513
DGRP_528
DGRP_530
DGRP_531
DGRP_535
DGRP_551
DGRP_555
DGRP_566
DGRP_584
DGRP_589
DGRP_596
DGRP_630
DGRP_634
DGRP_639
DGRP_642
DGRP_703
DGRP_714
DGRP_721
DGRP_727
DGRP_730
DGRP_737
DGRP_738
DGRP_748
DGRP_787
DGRP_790
DGRP_799
DGRP_801
DGRP_802
DGRP_804
DGRP_818
DGRP_819
DGRP_820
DGRP_822
DGRP_837
DGRP_849
DGRP_850
DGRP_852
DGRP_853
DGRP_861
DGRP_882
DGRP_884
DGRP_887
DGRP_890
DGRP_894
DGRP_897
DGRP_900
DGRP_907
DGRP_908
Download
Back to studies